Integrity,Innovation,Reliability,Responsibility

Hinova Pharmaceuticals’ Class 1 New Drug Deutenzalutamide Soft Capsules Approved for Marketing! A Breakthrough in Domestic Innovation for Prostate Cancer Treatment in China!

Time:2025-05-29 Source:海创药业 Hits:75

On May 29, 2025, it was announced via the National Medical Products Administration (NMPA) website that Haina’an® (generic name: Deutenzalutamide Soft Capsules), a Class 1 new drug independently developed by Hinova Pharmaceuticals (688302.SH), has received NMPA approval for marketing. It is indicated for adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after treatment with abiraterone acetate and chemotherapy, and who have not previously received novel androgen receptor inhibitors. As a project supported by the National Major Science and Technology Project for New Drug Innovation, Deutenzalutamide Soft Capsules represent the first domestically developed innovative drug approved in China for this indication.


According to GLOBOCAN 2022 data, prostate cancer is a common malignant tumor of the urinary system, ranking second in incidence and fifth in mortality among cancers in men globally. In 2022, there were approximately 1.467 million new cases of prostate cancer worldwide. In recent years, the incidence of prostate cancer in China has shown an upward trend, with 134,000 new cases reported in 2022. For metastatic castration-resistant prostate cancer, endocrine therapy remains the recommended first-line treatment.


About Deutenzalutamide Soft Capsules


Deutenzalutamide Soft Capsules (formerly known as HC-1119 Soft Capsules) is a Class 1 new drug independently developed by the company for the treatment of mCRPC. It is a second-generation androgen receptor (AR) inhibitor and has received support from the National Major Science and Technology Project for New Drug Innovation. The Phase 3 clinical study of Deutenzalutamide (HC-1119) in China has met its primary endpoint. Data show that, compared with the control group, Deutenzalutamide significantly prolonged progression-free survival (PFS) and reduced the risk of disease progression or death by 42% (HR=0.58, 95% CI: 0.439–0.770; p=0.0001).


The Phase 3 clinical data of Deutenzalutamide (HC-1119) conducted in China were selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023. The HC-1119-04 registration study of Deutenzalutamide was included in the 2023 edition of the CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer. As the first domestically developed innovative drug approved for this indication in China, Deutenzalutamide Soft Capsules demonstrate excellent safety profiles compared to other novel endocrine therapies. It can significantly reduce the incidence of central nervous system adverse events (such as seizures and falls), has no rash-related adverse reactions, and reduces the risk of common complications in elderly patients.


Good Medicines to Benefit the World: Bringing Chinese Innovation to the Globe

With the approval of Deutenzalutamide, Hinova Pharmaceuticals is accelerating its commercialization process. The company has built an R&D and production base in Chengdu that meets international GMP standards and has assembled a professional marketing team to fully prepare for the product launch.



Dr. Chen Yuanwei, Founder and Chairman of Hinova Pharmaceuticals, stated: "Deutenzalutamide is the 'opening masterpiece' of Hinova's decade-long dedication. Its development journey spans ten years, showcasing Hinova Pharmaceuticals' persistent innovation capabilities. We look forward to this 'Intelligent Manufacturing in China' innovative drug providing patients with safer and more effective treatment options. Deutenzalutamide is merely the starting point of Hinova Pharmaceuticals' innovation journey. In the future, we will promote the commercialization of more products. Guided by the mission of 'Creating Good Medicines to Benefit the World,' Hinova Pharmaceuticals will continue to invest in the construction of cutting-edge technology platforms to develop innovative drugs with global rights, bringing Chinese wisdom to patients worldwide."


Disclaimer:

1. This article is intended solely to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not promotional material. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.

2. The information contained herein is derived from relevant research reports and clinical data and is for reference only. Please follow the guidance of physicians or other qualified healthcare professionals.

3. Any information involving unapproved products refers to assets still in development or clinical trials and involves uncertainties. Final outcomes are subject to approval by the National Medical Products Administration.

 

Hinova Pharmaceuticals (688302.SH) is a global innovative drug company focused on cancer and metabolic diseases. Guided by its mission, “Creating Good Medicines to Benefit the World,” the company prioritizes providing patients with effective, safe, and affordable therapies, and is committed to developing and manufacturing innovative drugs that address significant unmet clinical needs and carry global rights.

The company operates four core technology platforms: the PROTAC Targeted Protein Degradation Platform, the Deuterated Drug Development Platform, the Targeted Drug Discovery and Validation Platform, and the Translational Medicine Technology Platform. It has been selected for two National “Major New Drug Creation” Science and Technology Major Projects and multiple provincial and municipal research programs. Hinova currently has eight products in development and one product approved for marketing. Its management team brings extensive drug research and development experience, with many core members coming from leading global pharmaceutical companies.

Current product pipeline:

· Deutenzalutamide (HC-1119), an AR inhibitor: The China Phase 3 trial has reached its primary endpoint; Phase 3 data were presented at the June 2023 ASCO Annual Meeting; the HC-1119-04 registration study was included in the 2023 CSCO Prostate Cancer Diagnosis and Treatment Guidelines; the new drug application was accepted by China’s NMPA in November 2023; and Deutenzalutamide Soft Capsules were officially approved for marketing by China’s NMPA on May 29, 2025.

· HP501, a URAT1 inhibitor: Monotherapy trials for hyperuricemia/gout have completed multiple Phase 1/2 studies. The U.S. FDA approved its Phase 2 trial for gout-related hyperuricemia in December 2023, and NMPA approved the China IND for combination therapy with the xanthine oxidase inhibitor febuxostat in April 2024.

· HP518, an oral AR PROTAC: It is the first oral AR PROTAC candidate in China to enter clinical development. The China Phase 1/2 trial application for metastatic castration-resistant prostate cancer (mCRPC) was approved by NMPA in November 2023, with first patient dosing in December 2023. The China Phase 1 tolerability study has been completed, and the first patient in the China Phase 2 trial was enrolled in December 2024. The U.S. FDA approved the same-indication IND in January 2023. The Australian Phase 1 trial has been completed, with results selected for ASCO-GU 2024 and ASCO 2024. In June 2024, HP518 received FDA Fast Track designation for AR-positive triple-negative breast cancer.

· HP568, an oral PROTAC drug for ER+/HER2− advanced breast cancer: The China clinical trial application was approved by NMPA in October 2024. The U.S. FDA approved the same-indication IND in December 2024.

· HP515 for non-alcoholic steatohepatitis: The China clinical trial application was approved by NMPA in August 2024, with first patient enrollment in January 2025. The U.S. FDA approved the clinical trial application for metabolic steatohepatitis in September 2024.

· HP537 for hematologic malignancies: The China clinical trial application was approved by NMPA in February 2024, and the U.S. FDA approved the Phase 1/2 trial application for the same indication in July 2024.

· HP560 for myelofibrosis: The China clinical trial application was approved by NMPA in July 2024.